CRYOPORT, INC. (NASDAQ: CYRX)
SECOND QUARTER 2026 IN REVIEW
August 6, 2026

Important information

This document provides a review of Cryoport, Inc.'s operational performance during the second quarter (Q2) of 2026, covering the three-month period ended June 30, 2026, and a general business outlook, supplementing our Q2 2026 earnings release. It is designed to be read by interested parties before the regularly scheduled quarterly conference call, which, for this quarter, is scheduled for 5:00 p.m. ET on Thursday, August 6, 2026. Therefore, the conference call will be in the format of a questions and answers session and will address any questions the investment community has regarding the Company's results.

Conference Call Information

Date:	August 6, 2026
Time:	5:00 p.m. ET
Dial-in numbers:	1-800-717-1738 (U.S.), 1-646-307-1865 (International)
Confirmation code:	Request the "Cryoport Call" or Conference ID: 1142151
Live webcast:	'Investor Relations' section at www.cryoportinc.com or click here. Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

Questions and answers will be recorded and available approximately three hours after completion of the live event on the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers, please follow this link. A dial-in replay of the call will also be available to those interested, until August 13, 2026. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1142151#.

SECOND QUARTER 2026 FINANCIAL RESULTS OVERVIEW

Business description	***Cryoport, Inc. (Nasdaq: CYRX)*** *is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with a strategic focus on supporting the development and commercialization of cell and gene therapies. Leveraging advanced technologies, proprietary logistics systems, and industry-leading expertise, Cryoport delivers mission-critical services that ensure the safe, compliant, and efficient transport, storage, and monitoring of temperature-sensitive biopharmaceutical materials.*
Client Examples	• **Biopharma/Pharma:** *Bristol Myers Squibb, Gilead, Vertex Pharma, Crispr Therapeutics, Lonza, J&J, Thermo Fisher Scientific, Iovance* • **Animal Health:** *Zoetis, Genus PLC, Boehringer Ingelheim, Elanco* • **Reproductive Medicine:** *TMRW/Reprotech, Inception, CCRM, IVI RMA, Pinnacle Fertility, Virtus Health, Carrot Fertility, Monash Fertility*
Revenue	Q2 2026: $49.0 million (+8% YoY)
Number of Global Clinical Trials Currently Supported	779 clinical trials - 94 in Phase 3
2026 Full Year Revenue Guidance	$192.0 - $196.0 million
Cash, Cash Equivalents & Short-Term Investments	$396.7 million
CEO	Jerrell Shelton

Revenue Momentum Continues

Our revenue momentum from recent quarters continued into the second quarter, with total revenue reaching $49.0 million. Revenue from the support of commercial Cell and Gene Therapies (CGT) grew 9% year-over-year to $9.4 million, driven by **strong 26% growth in Life Science Services revenue supporting commercial CGT programs**, partially offset by the absence of periodic commercial CGT Life Sciences Products revenue recognized in the prior-year period. Revenue from supporting CGT clinical trials increased 12% year-over-year to $13.4 million for the quarter. These results underscore the continued strength of our industry-leading position and the sustained growth of the global CGT market.



At the reportable segment level, our Life Sciences Services business delivered another strong quarter, reflecting the value of Cryoport's integrated, end-to-end platform across the life sciences ecosystem as well as the growing adoption of CGT. Revenue in this reporting segment grew 15% year-over-year, led by 25% growth in BioStorage/BioServices. Life Sciences Services revenue accounted for 57% of our total revenue for the second quarter, further demonstrating the increasing contribution of our high-growth services portfolio.



Our Life Sciences Products business also delivered solid results for the quarter. This was driven by continued demand for MVE Biological Solutions' (MVE) industry-leading cryogenic systems, including strong demand from Animal Health customers as well as improved demand from the Americas region. As the global market leader in cryogenic equipment, MVE remains a consistent generator of positive cash flow while also providing important strategic synergies that enhance and support our Life Sciences Services business.



CGT Market - Increasing Funding and Delivery

The global CGT market continues to advance rapidly. According to Evaluate Pharma, the cell therapy market is expected to grow at a 28% CAGR through 2030. This growth is being fueled by continued U.S. Food and Drug Administration (FDA) approvals, a healthy clinical pipeline, increased R&D and further developments in medical technology.



Specifically, funding for CGT companies was $9.4 billion in the first half of 2026, which is a very strong start after the industry raised a total $11.1 billion in 2025.



CGT delivery is also expanding, having evolved from originally being carried out by a small set of academic centers into a broader mix of large treatment sites and community providers. This trend is expected to accelerate due to the removal of Risk Evaluation & Mitigation Strategy (REMS) requirements by the FDA in June 2025 and the addition of more patient friendly label updates for CD-19 and BCMA-directed autologous CAR-T therapies. According to a recent whitepaper by the Alliance for Regenerative Medicine, between 2018 and 2025, the number of CGT administering sites in the U.S. increased by over 170%, while the number of CGT claims grew by approximately 740%.



Cryoport continues to support the industry's largest portfolio of clinical and commercial CGTs. At quarter end, we supported 22 commercial cell and gene therapies and our total clinical trial count rose to 779 clinical trials worldwide. Of these trials, 94 were in Phase 3 and 369 were in Phase 2. Approximately 59% of the global clinical trials supported by Cryoport were autologous cell therapies, 29% were allogeneic cell therapies, 6% were gene therapies, and 6% were vaccines, biologics and other trials. We believe this commanding position will enable us to drive further commercial growth as more therapies receive regulatory approvals.

Patients First: Supporting the Therapies of Tomorrow



Trial count as of the end of the respective periods

By geographic region, as of June 30, 2026, Cryoport supported 579 trials in the Americas, 145 in EMEA, and 55 in APAC (Asia-Pacific). This compares to 556 in the Americas, 124 in EMEA, and 48 in APAC as of June 30, 2025.

Cryoport Supported Clinical Trials by Phase

Clinical Trials	June 30,		
	2024	2025	2026
Phase 1	286	304	316
Phase 2	322	342	369
Phase 3	76	82	94
Total	**684**	**728**	**779**

Cryoport Supported Clinical Trials by Region

Clinical Trials	June 30,		
	2024	2025	2026
Americas	525	556	579
EMEA	114	124	145
APAC	45	48	55
Total	**684**	**728**	**779**

In Q2 2026, four (4) of our customers filed Biologics License Applications (BLA) / Marketing Authorization Applications (MAA). For the balance of 2026, we anticipate another 11 application

filings, five (5) possible additional new therapy approvals, and one (1) additional possible approval for label/geographic expansion from our customer base.

During the Q2 2026, Cryoport's customer, Orca Bio, received FDA approval for TREGZI™ as the first and only precision-engineered cell therapy for allogeneic stem cell transplant in the treatment of adults with hematological malignancies. TREGZI is a personalized treatment manufactured for each individual patient using living cells from a matched donor. TREGZI uses hematopoietic stem and progenitor cells (HSPCs) to reconstitute the immune system, highly purified regulatory T cells (Tregs) to suppress GVHD and conventional T cells (Tcons) to accelerate immune reconstitution and produce graft-versus-leukemia (GVL) activity. The FDA approval of TREGZI is based on results from the randomized, multi-center Precision-T Phase 3 study of patients (n=187) with a median age of 43.6 years (range 19-65 years) with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and mixed-phenotype acute leukemia (MPAL).

Additionally, during Q2 2026, Vertex Pharmaceuticals received supplemental approval from the FDA to expand the label of CASGEVY® for the treatment of patients aged 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved gene therapy indicated for children as young as 2 years for both SCD and TDT. In the United States, CASGEVY was approved using the Commissioner's National Priority Voucher. Vertex has also recently completed regulatory submissions in the Kingdom of Saudi Arabia and United Kingdom to expand the use of CASGEVY to children as young as five. Vertex has established a network of independently operated, authorized treatment centers (ATCs) throughout the U.S. to offer CASGEVY to eligible patients through existing access and reimbursement pathways. Today, there are more than 75 activated ATCs in the U.S. The full list can be accessed at CASGEVY.com.

Celebrating Our Milestones

We also celebrated a number of operational milestones in the second quarter. For example, Cryoport Systems' IntegriCell® cryopreservation services now has clinical processes running in both Houston, TX and Liège, Belgium. We were selected by Verismo Therapeutics to support its two clinical-stage KIR-CAR T cell therapy programs.

Verismo is the only company developing the KIR-CAR platform, using a modified NK cell-derived receptor and DAP12 pairing, designed to improve T cell functional persistence and reduce exhaustion, resulting in improved efficacy against challenging tumors. The KIR-CAR platform technology was developed specifically to address areas of high unmet medical need, including advanced solid tumors and B cell associated disorders and malignancies. We look forward to supporting Verismo as its programs continue to advance. IntegriCell is beginning to achieve its mission of bringing its scientific depth to the industry, which is one further supply chain improvement that we believe will allow the cell therapy industry to further scale.

Future Growth Catalysts

During the past quarter, we continued to advance toward the planned launch of BioServices operations at our Global Supply Chain Center in Paris, France expected in the fourth quarter of 2026. At the same time, we also made further progress with the planned opening of our new Global Supply Chain Center in Santa Ana, California expected in the fourth quarter of 2026. These two new facilities add significantly to our Global Supply Chain Network and ability to deliver advanced global supply chain solutions to our life sciences clients worldwide.



MVE HE Series Freezer with CryoVerse™ Connect Controller

There was also significant completion of projects in our Life Sciences Products segment as MVE began shipping a number of new products, including our MVE Fusion 811 self-regenerating cryogenic freezer that operates without the need for cryogenic infrastructure and routine liquid nitrogen (LN_2) refills. It features a compact 32-inch-wide footprint, dry sample storage, and an integrated Q-Drive cryocooler. We also began producing cryogenic freezers in China and shipped our first orders of HE and Open Top freezers with CryoVerse™ Connect controllers.

As part of our efforts to improve productivity in our day-to-day operations, we are also advancing on the digital frontier and are progressing with meaningful AI applications that improve our productivity and advance our enterprise technology strategy. We are utilizing generative AI to automate routine tasks, analyze large datasets, manage risks, and expedite decision-making. We are providing our employees with enterprise-approved generative AI tools for innovative purposes and have already begun to see measurable results.

Outlook For H2 2026

As our results show, we delivered an excellent second quarter, generating growth across our key revenue streams. Moving forward, we will remain focused on executing our strategy, driving continued financial performance, and capitalizing on the significant opportunities before us. Reflecting our strong performance for the first half of 2026, we are reaffirming our full-year 2026 revenue guidance of $192.0 million to $196.0 million.

The Company's 2026 guidance is dependent on its current business and expectations, which may be impacted by, among other things, factors that are outside of our control, such as national economic factors, the global macroeconomic and geopolitical environment, supply chain constraints, inflationary pressures, tariffs and other trade restrictions and/or the effects of foreign currency fluctuations, as well as the other factors described in the Company's filings with the Securities and Exchange Commission ("SEC"), including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC.

Second Quarter 2026 Financial Results

Please refer to the Q2 2026 Earnings Release published on our website www.cryoportinc.com under *Investor Relations*.

Upcoming Financial Conferences

Cryoport's management team frequently participates in financial conferences and other industry events, including virtual conferences, to ensure it is in regular communication with the investment community. Upcoming Company participations are shown in the following table:

Host	Conference	Date	Location
Needham	MedTech Conference	August 10, 2026	Virtual
Wells Fargo	Healthcare Conference	September 8-10, 2026	Boston
Jefferies	Healthcare Services Conference	September 14-15, 2026	Nashville, TN
UBS	Global Healthcare Conference	November 8-11, 2026	Palm Beach, FL
Jefferies	Global Healthcare Conference	November 16-19, 2026	London, UK
Stephens	Annual Growth Conference	November 17-19, 2026	Nashville, TN
BTIG	Digital Healthcare Forum	November 23, 2026	Virtual

Forward-Looking Statements

Statements in this document which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the Company's outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of the Company's clients. Forward-looking statements also include those related to the Company's plans regarding its Global Supply Chain Centers, including expected timing of future openings, the Company's belief that the results of its initiatives will continue progressively over the coming quarters and that the Company is positioned to drive more efficiencies, more scale in its operations, and continued margin expansion, the Company's belief that its strong balance sheet and liquidity sources give it the financial flexibility to keep advancing its strategic growth initiatives, the Company's belief that its industry position will enable it to drive further commercial growth as more therapies receive regulatory approvals, and the Company's expectation that upcoming growth catalysts in its business segments will drive the Company to new heights. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing economic and geopolitical conditions, such as those resulting from the war with Iran, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in the Company's cash flow, market acceptance risks, the effects of tariffs and other trade restrictions, and technical development risks. The Company's business could be affected by other factors discussed in the Company's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this document speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements in this document.

About Cryoport, Inc.

Cryoport, Inc. (Nasdaq: CYRX), is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized BioLogistics, BioStorage, BioServices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are ***"Enabling the Future of Medicine™."***

Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.x.com/cryoport for live updates.